相关实验视频

Updated: Jul 19, 2025

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

可溶性CD24是早期和血清阴性类风湿性关节炎的炎症生物标志物

Xi Zheng^1,2, Ping Wang¹, Jing Song^1,2

¹Department of Rheumatology and Immunology, Peking University People's Hospital & Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis, Beijing, China.

Annals of medicine

|August 17, 2023

概括

溶性CD24 (sCD24) 是一种对类风湿性关节炎 (RA) 疾病活性有前途的生物标志物. 它在RA患者中升高,特别是在早期或血清阴性疾病患者中,具有诊断潜力.

科学领域:

免疫学免疫学免疫学
类风湿病学类风湿病学
生物标志物发现发现

背景情况:

类风湿性关节炎 (RA) 是一种全身性自身免疫性疾病,导致关节炎症和骨破坏.
像ESR和CRP这样的标准炎症标志物在大量活跃的RA患者中可能是正常的.
需要可靠的生物标志物来评估RA疾病活性,特别是在特定的患者亚组中.

研究的目的:

评估可溶性CD24 (sCD24) 作为类风湿性关节炎 (RA) 疾病活性生物标志物的性能和临床意义.
将RA患者的sCD24水平与其他类风湿性疾病和健康个体的sCD24水平进行比较.
研究sCD24在早期和血清阴性RA患者群体中的实用性.

主要方法:

血清样本从269名RA患者,59名原发性Sjogren综合征患者,81名全身性红斑狼患者,76名骨关节炎患者和97名健康个体中收集.
溶性CD24 (sCD24) 度使用酶相关免疫吸收试验 (ELISA) 进行测量.
分析了sCD24水平与RA疾病活动状态,疾病持续时间和炎症指标相关.

主要成果:

与其他类风湿性疾病 (380-520 pg/mL) 和健康人群 (320 pg/mL) 相比,RA患者的血清sCD24水平显著升高 (2970 pg/mL).
在早期RA患者中的66.67%和在血清阴性RA患者中的61.11%观察到升高的sCD24.
sCD24度与疾病持续时间和其他炎症标志物有显著的相关性.

结论:

可溶性CD24 (sCD24) 显示出作为一种有价值的类风湿性关节炎 (RA) 炎症生物标志物的潜力.
sCD24对于评估早期RA和血清阴性RA患者的疾病活性特别有用.
对sCD24的进一步研究可能会改善类风湿性关节炎的治疗.

关键词:

可溶性CD24是一种可溶性CD24.疾病活动的疾病活动.类风湿性关节炎类风湿性关节炎

更多相关视频

Differentiation of Functional Osteoclasts from Human Peripheral Blood CD14+ Monocytes

Differentiation of Functional Osteoclasts from Human Peripheral Blood CD14+ Monocytes

Published on: January 27, 2023

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry

Published on: June 26, 2018

相关概念视频

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...